Frontier Pipeline: DLL3 Trispecifics, PSMA Radioligands, B7-H3 ADCs—and a First Look at EPR-Imaging PET

Among 25 fresh studies, several stand out:

• XB628 (NKG2A / PD-L1 bispecific) opens the door for NK-cell activation in advanced solid tumors.
• Ifinatamab deruxtecan vs docetaxel could make B7-H3 ADCs the next line of attack in mCRPC.
• Tarlatamab + YL201 ± anti-PD-L1 pairs DLL3 T-cell engagement with a B7-H3 ADC in tough SCLC.
• **177Lu-PSMA-617 “super-scan” pilot**tests radioligand therapy in the very bone-dominant mCRPC population once excluded from VISION.
• LASER trial of 177Lu-PSMA-617 in clear-cell RCC pushes PSMA targeting beyond prostate cancer.
• [89Zr]DFO-starPEG PET pioneers whole-body imaging of the EPR effect—potentially a new biomarker for nanoparticle or ADC delivery efficiency.

Get Oncology Intel from Sagely Health delivered to your inbox each week.